Key result
In adult C57 mice with experimental diabetes, NADPH oxidase inhibition with apocynin significantly attenuated or ablated diabetes-induced reductions in myocardial contractile function.
Why the study?
Does NADPH oxidase inhibition with apocynin improve myocardial contractile dysfunction in a mouse model of diabetes?
Does NADPH oxidase inhibition with apocynin improve myocardial contractile dysfunction in a mouse model of diabetes?
Inhibition of NADPH oxidase with apocynin alleviates myocardial contractile dysfunction and reduces oxidative stress in a mouse model of diabetic cardiomyopathy.
Supports NADPH oxidase inhibition research in diabetic cardiomyopathy; no current clinical implications.
AIM: O(2) (-) production is implicated in cardiac dysfunction for a number of diseases including diabetes. Activation of the O(2) (-)-producing enzyme NADPH oxidase is seen in diabetes, although its role in diabetic cardiomyopathy is unclear. This study was designed to evaluate the effect of NADPH oxidase inhibition on cardiac function in diabetes. METHODS: Experimental diabetes was induced in adult C57 mice using streptozotocin (STZ, 150 mg/kg, i.p.) prior to the administration of the NADPH oxidase inhibitor apocynin (4 mg/kg/day) for 2 weeks. Left ventricular (LV) and myocyte contractile functions were evaluated using echocardiography and edge-detection, respectively. RESULTS: STZ elicited hyperglycaemia and reduced body weight gain, which was unaffected by apocynin. STZ significantly reduced fractional shortening, LV wall thickness, peak shortening, maximal velocity and duration of shortening or relengthening, the effects of which - with the exception of wall thickness - were significantly attenuated or ablated by apocynin. Western blot analysis revealed that the effects of comparable Akt phosphorylation, reduced AMPK phosphorylation, downregulation of sarco(endo)plasmic reticulum Ca(2+)-ATPase and lessened phosphorylation of phospholamban in diabetic myocardium were unaffected by apocynin. Both apocynin and the nitric oxide synthase (NOS) inhibitor l-arginine methyl ester (L-NAME) inhibited elevated O(2) (-) production in diabetes without any additive effect between the two, indicating the presence of endothelial nitric oxide synthase (eNOS) uncoupling. However, neither diabetes nor apocynin altered the expression of heat shock protein 90 and eNOS phosphorylation (Ser(1177)). In addition, apocynin mitigated elevated levels of nitrotyrosine and nitric oxide in diabetes. CONCLUSION: Taken together, these data indicate the beneficial role of NADPH oxidase inhibition in diabetes-induced myocardial contractile dysfunction.
No takes yet. Share an insight, caveat, or question.
Roe et al. (2011) studied Experimental diabetes-induced myocardial contractile dysfunction. Apocynin vs. Diabetic control was evaluated on Left ventricular (LV) and myocyte contractile functions. In adult C57 mice with experimental diabetes, NADPH oxidase inhibition with apocynin significantly attenuated or ablated diabetes-induced reductions in myocardial contractile function.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: